Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer

Journal of Controlled Release

Volumn 171, Issue 3, 2013, Pages 322-329

  Ding, Hui ^a   Helguera, Gustavo ^a,b,d   Rodríguez, José A ^b,c   Markman, Janet ^a   Luria Pérez, Rosendo ^b,e   Gangalum, Pallavi ^a   Portilla Arias, Jose ^a   Inoue, Satoshi ^a,f   Daniels Wells, Tracy R ^b   Black, Keith ^a   Holler, Eggehard ^a   Penichet, Manuel L ^b,c   Ljubimova, Julia Y ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^e Children's Hospital of Mexico Federico Gomez   (Mexico)

^f SAGA UNIVERSITY   (Japan)

Author keywords

Antibody IL 2 fusion protein; Breast cancer; HER2 neu; Laminin 411; Nanobioconjugate; Polymalic acid

Indexed keywords

ANTIBODIES; BIOACTIVITY; CELLS; DISEASES; ENZYME ACTIVITY; IMMUNE SYSTEM; OLIGONUCLEOTIDES; PROTEINS; TUMORS;

BREAST CANCER; FUSION PROTEINS; HER2/NEU; LAMININ; NANOBIOCONJUGATE; POLYMALIC ACID;

DIAGNOSIS;

ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYBRID PROTEIN; IMMUNOGLOBULIN G3 ANTIBODY; INTERLEUKIN 2; LAMININ 411; NANOCONJUGATE; POLYCEFIN; POLYMALIC ACID; POLYMER; RECOMBINANT INTERLEUKIN 2; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; COVALENT BOND; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; SURVIVAL RATE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANTIBODY-IL-2 FUSION PROTEIN; BREAST CANCER; HER2/NEU; LAMININ-411; NANOBIOCONJUGATE; POLYMALIC ACID;

ANIMALS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNIZATION; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; INTERLEUKIN-2; MALATES; MICE; MICE, NUDE; POLYMERS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS;

EID: 84892937594     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.06.001     Document Type: Article

References (59)

1. R. Siegel, D. Naishadham, A. Jemal, Cancer statistics, 2013, CA Cancer J. Clin. 63 (1) (2013) 11-30.
2. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, W.L. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235 (4785) (1987) 177-182. (Pubitemid 17231334)
3. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, W.J. Levin, S.G. Stuart, J. Udove, A. Ullrich, M.F. Press, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science 244 (4905) (1989) 707-712. (Pubitemid 19147683)
4. M.F. Press, M.C. Pike, G. Hung, J.Y. Zhou, Y. Ma, J. George, J. Dietz-Band, W. James, D.J. Slamon, J.G. Batsakis, A.K. El-Naggar, Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis, Cancer Res. 54 (21) (1994) 5675-5682. (Pubitemid 24346266)
5. B.G. Haffty, F. Brown, D. Carter, S. Flynn, Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study, Int. J. Radiat. Oncol. Biol. Phys. 35 (4) (1996) 751-757. (Pubitemid 26251130)
6. R. Nahta, F.J. Esteva, Trastuzumab: triumphs and tribulations, Oncogene 26 (25) (2007) 3637-3643. (Pubitemid 46842713)
7. M.D. Pegram, T. Pienkowski, D.W. Northfelt, W. Eiermann, R. Patel, P. Fumoleau, E. Quan, J. Crown, D. Toppmeyer, M. Smylie, A. Riva, S. Blitz, M.F. Press, D. Reese, M.A. Lindsay, D.J. Slamon, Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer, J. Natl. Cancer Inst. 96 (10) (2004) 759-769. (Pubitemid 38771821)
8. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, L. Norton, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med. 344 (11) (2001) 783-792. (Pubitemid 32222155)
9. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher, D.J. Slamon, M. Murphy, W.F. Novotny, M. Burchmore, S. Shak, S.J. Stewart, First-line Herceptin monotherapy in metastatic breast cancer, Oncology 61 (Suppl. 2) (2001) 37-42. (Pubitemid 33033423)
10. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher, D.J. Slamon, M. Murphy, W.F. Novotny, M. Burchmore, S. Shak, S.J. Stewart, M. Press, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J. Clin. Oncol. 20 (3) (2002) 719-726. (Pubitemid 34111379)
11. J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, L. Dantis, N.T. Sklarin, A.D. Seidman, C.A. Hudis, J. Moore, P.P. Rosen, T. Twaddell, I.C. Henderson, L. Norton, Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer, Semin. Oncol. 26 (4 Suppl. 12) (1999) 78-83. (Pubitemid 29411436)
12. Y.C. Wang, G. Morrison, R. Gillihan, J. Guo, R.M. Ward, X. Fu, M.F. Botero, N.A. Healy, S.G. Hilsenbeck, G.L. Phillips, G.C. Chamness, M.F. Rimawi, C.K. Osborne, R. Schiff, Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation, Breast Cancer Res. 13 (6) (2011) R121.
13. A.A. Brandes, E. Franceschi, A. Tosoni, R. Degli Esposti, Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls, Expert Rev. Anticancer Ther. 10 (2) (2010) 179-184.
14. B. Markman, J. Tabernero, Monoclonal antibodies in solid tumours, Curr. Clin. Pharmacol. 5 (3) (2010) 160-165.
15. R. Nahta, F.J. Esteva, Herceptin: mechanisms of action and resistance, Cancer Lett. 232 (2) (2006) 123-138. (Pubitemid 43170962)
16. R. Whittington, D. Faulds, Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer, Drugs 46 (3) (1993) 446-514. (Pubitemid 23292121)
17. S. Negrier, J. Maral, M. Drevon, J. Vinke, B. Escudier, T. Philip, Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe, Cancer J. Sci. Am. 6 (Suppl. 1) (2000) S93-S98.
18. J.P. Siegel, R.K. Puri, Interleukin-2 toxicity, J. Clin. Oncol. 9 (4) (1991) 694-704.
19. S.A. Rosenberg, M.T. Lotze, J.C. Yang, P.M. Aebersold, W.M. Linehan, C.A. Seipp, D.E. White, Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients, Ann. Surg. 210 (4) (1989) 474-484, (discussion 484-475).
20. G. Helguera, S.L. Morrison, M.L. Penichet, Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy, Clin. Immunol. 105 (3) (2002) 233-246. (Pubitemid 36016051)
21. E. Ortiz-Sanchez, G. Helguera, T.R. Daniels, M.L. Penichet, Antibody-cytokine fusion proteins: applications in cancer therapy, Expert Opin. Biol. Ther. 8 (5) (2008) 609-632. (Pubitemid 351685026)
22. M.L. Penichet, J.S. Dela Cruz, S.U. Shin, S.L. Morrison, A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors, Hum. Antibodies 10 (1) (2001) 43-49. (Pubitemid 32328605)
23. M.L. Phillips, M.H. Tao, S.L. Morrison, V.N. Schumaker, Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization, Mol. Immunol. 31 (15) (1994) 1201-1210. (Pubitemid 24330697)
24. E.M. Hiltbold, A.M. Vlad, P. Ciborowski, S.C. Watkins, O.J. Finn, The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells, J. Immunol. 165 (7) (2000) 3730-3741. (Pubitemid 32057279)
25. J.S. Dela Cruz, K.R. Trinh, H.W. Chen, A. Ribas, S.L. Morrison, M.L. Penichet, Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies, Mol. Immunol. 43 (6) (2006) 667-676. (Pubitemid 41785395)
26. G. Helguera, J.A. Rodriguez, M.L. Penichet, Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors, Mol. Cancer Ther. 5 (4) (2006) 1029-1040. (Pubitemid 43724604)
27. J.S. Dela Cruz, S.Y. Lau, E.M. Ramirez, C. De Giovanni, G. Forni, S.L. Morrison, M.L. Penichet, Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice, Vaccine 21 (13-14) (2003) 1317-1326. (Pubitemid 36263173)
28. J.S. Dela Cruz, S.L. Morrison, M.L. Penichet, Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein, Vaccine 23 (39) (2005) 4793-4803. (Pubitemid 41557330)
29. G. Helguera, J.S. Dela Cruz, C. Lowe, P.P. Ng, R. Trinh, S.L. Morrison, M.L. Penichet, Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors, Vaccine 24 (3) (2006) 304-316. (Pubitemid 41790434)
30. F.J. Esteva, V. Valero, D. Booser, L.T. Guerra, J.L. Murray, L. Pusztai, M. Cristofanilli, B. Arun, B. Esmaeli, H.A. Fritsche, N. Sneige, T.L. Smith, G.N. Hortobagyi, Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer, J. Clin. Oncol. 20 (7) (2002) 1800-1808. (Pubitemid 34273269)
31. A.D. Seidman, M.N. Fornier, F.J. Esteva, L. Tan, S. Kaptain, A. Bach, K.S. Panageas, C. Arroyo, V. Valero, V. Currie, T. Gilewski, M. Theodoulou, M.E. Moynahan, M. Moasser, N. Sklarin, M. Dickler, G. D'Andrea, M. Cristofanilli, E. Rivera, G.N. Hortobagyi, L. Norton, C.A. Hudis, Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification, J. Clin. Oncol. 19 (10) (2001) 2587-2595. (Pubitemid 32441364)
32. R.A. Reisfeld, The tumor microenvironment: a target for combination therapy of breast cancer, Crit. Rev. Oncog. 18 (1-2) (2013) 115-133.
33. H. Fujiwara, Y. Kikkawa, N. Sanzen, K. Sekiguchi, Purification and characterization of human laminin-8. Laminin-8 stimulates cell adhesion and migration through alpha3beta1 and alpha6beta1 integrins, J. Biol. Chem. 276 (20) (2001) 17550-17558.
34. J. Thyboll, J. Kortesmaa, R. Cao, R. Soininen, L. Wang, A. Iivanainen, L. Sorokin, M. Risling, Y. Cao, K. Tryggvason, Deletion of the laminin alpha4 chain leads to impaired microvessel maturation, Mol. Cell. Biol. 22 (4) (2002) 1194-1202. (Pubitemid 34094855)
35. M. Patarroyo, K. Tryggvason, I. Virtanen, Laminin isoforms in tumor invasion, angiogenesis and metastasis, Semin. Cancer Biol. 12 (3) (2002) 197-207. (Pubitemid 34833063)
36. A.M. Gonzalez, M. Gonzales, G.S. Herron, U. Nagavarapu, S.B. Hopkinson, D. Tsuruta, J.C. Jones, Complex interactions between the laminin alpha 4 subunit and integrins regulate endothelial cell behavior in vitro and angiogenesis in vivo, Proc. Natl. Acad. Sci. U. S. A. 99 (25) (2002) 16075-16080. (Pubitemid 35462751)
37. M. Fujita, N.M. Khazenzon, S. Bose, K. Sekiguchi, T. Sasaki, W.G. Carter, A.V. Ljubimov, K.L. Black, J.Y. Ljubimova, Overexpression of beta1-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases, Breast Cancer Res. 7 (4) (2005) R411-R421.
38. M. Fujita, N.M. Khazenzon, A.V. Ljubimov, B.S. Lee, I. Virtanen, E. Holler, K.L. Black, J.Y. Ljubimova, Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis, Angiogenesis 9 (4) (2006) 183-191.
39. M. Fujita, B.S. Lee, N.M. Khazenzon, M.L. Penichet, K.A. Wawrowsky, R. Patil, H. Ding, E. Holler, K.L. Black, J.Y. Ljubimova, Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid), J. Control. Release 122 (3) (2007) 356-363. (Pubitemid 47411593)
40. J.Y. Ljubimova, M. Fugita, N.M. Khazenzon, A. Das, B.B. Pikul, D. Newman, K. Sekiguchi, L.M. Sorokin, T. Sasaki, K.L. Black, Association between laminin-8 and glial tumor grade, recurrence, and patient survival, Cancer 101 (3) (2004) 604-612. (Pubitemid 38970612)
41. H. Ding, S. Inoue, A.V. Ljubimov, R. Patil, J. Portilla-Arias, J. Hu, B. Konda, K.A. Wawrowsky, M. Fujita, N. Karabalin, T. Sasaki, K.L. Black, E. Holler, J.Y. Ljubimova, Inhibition of brain tumor growth by intravenous poly (beta-L-malic acid) nanobioconjugate with pH-dependent drug release [corrected], Proc. Natl. Acad. Sci. U. S. A. 107 (42) (2010) 18143-18148.
42. C. Braud, M. Vert, Degradation of poly(p-malic acid) - monitoring of oligomers formation by aqueous SEC and HPCE, Polym. Bull. 29 (1992) 177-183.
43. B. Gasslmaier, C.M. Krell, D. Seebach, E. Holler, Synthetic substrates and inhibitors of beta-poly(L-malate)-hydrolase (polymalatase), Eur. J. Biochem. 267 (16) (2000) 5101-5105. (Pubitemid 30641305)
44. B.-S. Lee, M. Vert, E. Holler, Water-soluble aliphatic polyesters: poly(malic acid)s, in: Y. Doi, A. Steinbüchel (Eds.), Biopolymers: Polyesters I, Vol. 3a, Wiley VCH, Weinheim, 2002, pp. 75-103.
45. W.Z. Wei, W.P. Shi, A. Galy, D. Lichlyter, S. Hernandez, B. Groner, L. Heilbrun, R.F. Jones, Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA, Int. J. Cancer 81 (5) (1999) 748-754. (Pubitemid 29214385)
46. G. Helguera, M.L. Penichet, Antibody-cytokine fusion proteins for the therapy of cancer, Methods Mol. Med. 109 (2005) 347-374.
47. B.S. Lee, M. Fujita, N.M. Khazenzon, K.A. Wawrowsky, S. Wachsmann-Hogiu, D.L. Farkas, K.L. Black, J.Y. Ljubimova, E. Holler, Polycefin, a new prototype of a multifunctional nanobioconjugate based on poly(beta-L-malic acid) for drug delivery, Bioconjug. Chem. 17 (2) (2006) 317-326.
48. B.S. Lee, M. Vert, E. Holler, Water-soluble Aliphatic Polyesters: Poly(malic acid)s, Wiley-VCH Verlag Gmbh, Weinheim, 2002.
49. S. Li, Z. Yang, X. Sun, Y. Tan, S. Yagi, R.M. Hoffman, A simultaneous colorimetric assay of free and protein-coupled polyethylene glycol, Anal. Biochem. 313 (2) (2003) 335-337. (Pubitemid 36259960)
50. S. Inoue, H. Ding, J. Portilla-Arias, J. Hu, B. Konda, M. Fujita, A. Espinoza, S. Suhane, M. Riley, M. Gates, R. Patil, M.L. Penichet, A.V. Ljubimov, K.L. Black, E. Holler, J.Y. Ljubimova, Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity, Cancer Res. 71 (4) (2011) 1454-1464.
51. T.R. Daniels, P.P. Ng, T. Delgado, M.R. Lynch, G. Schiller, G. Helguera, M.L. Penichet, Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells, Mol. Cancer Ther. 6 (11) (2007) 2995-3008. (Pubitemid 350206778)
52. G. Carlsson, L. Ekelund, L. Stigsson, L. Hafstrom, Vascularization and tumour volume estimations of solitary liver tumours in rats, Ann. Chir. Gynaecol. 72 (4) (1983) 187-191.
53. J.Y. Ljubimova, M. Fujita, N.M. Khazenzon, B.S. Lee, S. Wachsmann-Hogiu, D.L. Farkas, K.L. Black, E. Holler, Nanobioconjugate based on polymalic acid for tumor targeting, Chem. Biol. Interact. 171 (2) (2008) 195-203.
54. R. Patil, J. Portilla-Arias, H. Ding, B. Konda, A. Rekechenetskiy, S. Inoue, K.L. Black, E. Holler, J.Y. Ljubimova, Cellular delivery of doxorubicin via pH-controlled hydrazone linkage using multifunctional nano vehicle based on poly(beta-L-malic acid), Int. J. Mol. Sci. 13 (9) (2012) 11681-11693.
55. H. Ding, J. Portilla-Arias, R. Patil, K.L. Black, J.Y. Ljubimova, E. Holler, The optimization of polymalic acid peptide copolymers for endosomolytic drug delivery, Biomaterials 32 (22) (2011) 5269-5278.
56. H. Ding, J. Portilla-Arias, R. Patil, K.L. Black, J.Y. Ljubimova, E. Holler, Distinct mechanisms of membrane permeation induced by two polymalic acid copolymers, Biomaterials 34 (1) (2013) 217-225.
57. R.F. Minchin, D.J. Martin, Nanoparticles for molecular imaging-an overview, Endocrinology 151 (2) (2010) 474-481.
58. Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res. 46 (12 Pt 1) (1986) 6387-6392. (Pubitemid 17221789)
59. T.L. Stevens, A. Bossie, V.M. Sanders, R. Fernandez-Botran, R.L. Coffman, T.R. Mosmann, E.S. Vitetta, Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells, Nature 334 (6179) (1988) 255-258.